Loading...
Market
What will be ORLYNVAH's market share among oral antibiotics for UTIs in the US by December 31, 2025?
2
Resolution / Starting Odds
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Market share data from healthcare analytics firms or industry reports
Story
FDA Approves Iterum's Oral Antibiotic ORLYNVAH for Uncomplicated UTIs in Women on October 25, 2024
Oct 25, 2024, 03:58 PM
The U.S. Food and Drug Administration (FDA) has approved Iterum Therapeutics' oral antibiotic, ORLYNVAH, for the treatment of uncomplicated urinary tract infections (UTIs) in adult women. This announcement was made on Friday, October 25, 2024. The approval is significant as it addresses a common health issue among women, providing a new treatment option. The FDA's decision follows a period of heightened trading activity for Iterum Therapeutics, indicated by a notable increase in volume prior to the announcement. The company's market capitalization remains low, suggesting potential for growth following this approval.
View original story
Similar markets
0-10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
0-25% • 25%
25-50% • 25%
50-75% • 25%
Above 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%